About IntelliPharmaCeutics International (TSE:I)
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-150,985.50%
Return on Assets-141.70%
IntelliPharmaCeutics International (TSE:I) Frequently Asked Questions
What is IntelliPharmaCeutics International's stock symbol?
IntelliPharmaCeutics International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "I."
How were IntelliPharmaCeutics International's earnings last quarter?
IntelliPharmaCeutics International Inc. (TSE:I) posted its quarterly earnings results on Monday, April, 14th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.07. The business earned $5.14 million during the quarter, compared to analysts' expectations of $3.63 million. IntelliPharmaCeutics International had a negative net margin of 214.36% and a negative return on equity of 150,985.50%. View IntelliPharmaCeutics International's Earnings History.
When will IntelliPharmaCeutics International make its next earnings announcement?
Who are some of IntelliPharmaCeutics International's key competitors?
Some companies that are related to IntelliPharmaCeutics International include Newalta (NAL), Acerus Pharmaceuticals (ASP), Tree Island Steel (TSL), TransAtlantic Petroleum (TNP), Aura Minerals (ORA), Glacier Media (GVC), Perpetual Energy (PMT), Terago (TGO), Chinook Energy (CKE), Platinum Group Metals (PTM), Fortress Paper (FTP), Nexj Systems (NXJ), Trez Capital Mortgage Investment (TZZ), McCoy Global (MCB), Canadian Zinc (CZN), TAG Oil (TAO), Concordia International (CXR) and Horizons Active Cdn Dividend Etf (HAL).
Who are IntelliPharmaCeutics International's key executives?
IntelliPharmaCeutics International's management team includes the folowing people:
- Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
- Amina Odidi Ph.D., President, Chief Operating Officer, Director
- Andrew Patient, Chief Financial Officer
- John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
- Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
- Kenneth Keirstead, Independent Director
- Bahadur Madhani, Independent Director
- Eldon R. Smith M.D., Independent Director (Age 75)
How do I buy IntelliPharmaCeutics International stock?
Shares of IntelliPharmaCeutics International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IntelliPharmaCeutics International's stock price today?
One share of IntelliPharmaCeutics International stock can currently be purchased for approximately C$3.23.
How big of a company is IntelliPharmaCeutics International?
IntelliPharmaCeutics International has a market capitalization of C$35.92 million.
How can I contact IntelliPharmaCeutics International?
IntelliPharmaCeutics International's mailing address is 30 Worcester Rd, ETOBICOKE, ON M9W 5X2, Canada. The company can be reached via phone at +1-416-7983001.
MarketBeat Community Rating for IntelliPharmaCeutics International (I)MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
IntelliPharmaCeutics International (TSE:I) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
IntelliPharmaCeutics International (TSE:I) Earnings History and Estimates Chart
IntelliPharmaCeutics International (TSE I) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/9/2018|| || || || || || || || |
|4/14/2014||C$0.03||C$0.10||C$3.63 million||C$5.14 million||View||N/A|
IntelliPharmaCeutics International (TSE:I) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for IntelliPharmaCeutics International (TSE:I)
No dividend announcements for this company have been tracked by MarketBeat.com
IntelliPharmaCeutics International (TSE I) Insider Trading and Institutional Ownership History
IntelliPharmaCeutics International (TSE I) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/30/2015||Penna Domenic Della||Insider||Buy||3,510||C$2.10||C$7,371.00|
|11/25/2015||Penna Domenic Della||Insider||Buy||20,375||C$1.87||C$38,101.25|
IntelliPharmaCeutics International (TSE I) News Headlines
IntelliPharmaCeutics International (TSE:I) SEC Filings
Financials are not available for this stock.
IntelliPharmaCeutics International (TSE I) Stock Chart for Monday, December, 11, 2017